Cytokinetics appoints James M. Daly to Board of Directors as Class III member

CYTOKINETICS INC

James M. Daly appointed to Board effective August 19, 2025, as Class III director, term expiring at 2028 annual meeting.
Daly also appointed to Compliance Committee; determined independent under SEC and Nasdaq rules.
Annual director compensation: $50,000 retainer, $7,500 Compliance retainer, plus $440,000 equity grant.
Initial option grant of 27,450 shares ($700,000 fair value) vesting over three years.
No arrangements or transactions requiring disclosure under Item 404(a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.